Inivata Raises $35 million in Second Close of Series C Financing February 04, 2021 07:00 ET | Source: Inivata Inivata Inivata Raises $35 million in Second Close of Series C Financing Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung Research Triangle Park, NC, USA and Cambridge, UK, 4 February 2021 -- Inivata, a leader in liquid biopsy, today announces it has raised $35 million (£25.7 million) in a second close of a Series C financing round. The round was led by Soleus Capital, who were joined by new investors including Janus Henderson Investors and Farallon Capital alongside existing investor IP Group. This latest funding takes the total raised in the Series C to $60 million and follows the $25 million invested by NeoGenomics, Inc (NASDAQ: NEO) in 2020, alongside the formation of a strategic collaboration with Inivata.